Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) generates news across biotechnology, licensing, financing and corporate diversification activities. Company press releases highlight its evolution from a biotechnology focus into a diversified business with several divisions and an emphasis on becoming a revenue generating company. For followers of WINT news, this means updates can span drug development milestones, asset sales, licensing income opportunities, environmental services initiatives, fintech transactions and capital markets activity.
In the biotech arena, Windtree’s news flow has included interim data and scientific presentations for its cardiovascular drug candidate istaroxime and related SERCA2a activators, as well as decisions to adjust or terminate specific clinical studies based on resources and strategic priorities. The company has also reported on strengthening its patent estate for these cardiovascular assets and later announced an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC while retaining rights to a share of future proceeds and transferring certain development payables.
Windtree’s communications also cover its acute pulmonary franchise, where a global license agreement for RDS treatments such as SURFAXIN, lyophilized lucinactant and AEROSURF may generate milestone and royalty payments if development and commercialization progress under the licensee. Additional news items describe corporate strategy decisions, including a focus on environmental services and other revenue generating businesses, a letter of intent to acquire CommLoan, Inc. in the fintech and commercial real estate lending technology space, and the outcome of stockholder votes supporting financing flexibility.
Investors tracking WINT-related headlines will also see coverage of financing arrangements, preferred stock conversions, equity line of credit structures, and the company’s exploration of a BNB cryptocurrency treasury strategy, as well as its transition from the Nasdaq Capital Market to over-the-counter trading. Bookmarking this news feed can help readers monitor how Windtree’s mix of biotech assets, licensing agreements and diversified business initiatives evolves over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Windtree Therapeutics (NasdaqCM: WINT) has released findings from the SEISMiC Study, demonstrating that istaroxime significantly improves systolic blood pressure (SBP) in patients with early cardiogenic shock due to heart failure. The study showed a 93.6% relative increase in SBP AUC over the first 6 hours with the 1.0 μg/kg/min dose, compared to a 39.5% increase with the higher dose of 1.5 μg/kg/min. Importantly, istaroxime therapy did not worsen renal function. These results were published in the Journal of Cardiac Failure, highlighting the drug's potential as a first-in-class treatment for acute heart failure conditions. Dr. Steve Simonson from Windtree noted the findings will inform future development strategies for istaroxime.
Windtree Therapeutics has successfully completed its underwritten public offering of 3,686,006 shares of common stock, raising approximately $12.4 million before expenses. Each share was priced at $2.93 and sold alongside a warrant to purchase an additional share. The offering included the underwriter's full option to buy an additional 552,900 shares and warrants. Windtree plans to allocate up to $3.5 million of the net proceeds to extend enrollment and complete a Phase 2 clinical trial for istaroxime, a candidate for treating cardiogenic shock, with the remainder directed towards working capital. The securities were offered under Windtree's registration statement, effective April 19, 2023.
Windtree Therapeutics has announced the pricing for its underwritten public offering, consisting of 3,686,006 shares of common stock and warrants to purchase the same amount. The combined offering price is set at $2.93 per share and accompanying warrant, with an expected gross proceeds of approximately $10.8 million. Proceeds are earmarked primarily for the completion of a Phase 2 clinical trial for istaroxime in cardiogenic shock, with the remainder allocated for working capital. The offering is anticipated to close around April 24, 2023, pending standard closing conditions. Ladenburg Thalmann & Co. Inc. serves as the sole book running manager. Additionally, the underwriter has a 45-day option to purchase up to 552,900 shares or warrants. This offering has been filed with the SEC under Form S-1.
Windtree Therapeutics (NasdaqCM: WINT) announced that the European Patent Office has granted Patent No. 3599243, protecting a class of SERCA2a Activators for heart failure treatment until July 2038. This patent covers dual mechanism drug candidates that both activate SERCA2a and inhibit the Na+/K+ pump. Unlike existing treatments, these candidates may offer both intravenous and oral therapies for acute heart failure and chronic heart failure management.
CEO Craig Fraser highlighted the significance of SERCA2a activation in advancing heart failure treatment. Windtree's platform also includes istaroxime, a first-in-class therapy that improves cardiac function.
Windtree Therapeutics, Inc. (NasdaqCM: WINT) reported its financial results for Q4 and the fiscal year ending December 31, 2022. For Q4, the company reduced its operating loss to $10.8 million from $14.7 million in Q4 2021. The net loss was $9.7 million ($13.01 per share) compared to $13.1 million ($23.22 per share) the previous year. R&D expenses fell to $1.2 million in Q4 2022 from $4.5 million in Q4 2021, primarily due to focused resource allocation on the istaroxime pipeline. The company also issued a new patent for istaroxime, signaling advancement in its cardiovascular treatment efforts.
FAQ
What is the current stock price of Windtree Therapeutics (WINT)?
What is the market cap of Windtree Therapeutics (WINT)?
